
Katrien Lagrou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1757656/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Lung microbiota predict invasive pulmonary aspergillosis and its outcome in immunocompromised patients. Thorax, 2022, 77, 283-291.	2.7	19
2	Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients—a multinational observational study by the European Confederation of Medical Mycology. Clinical Microbiology and Infection, 2022, 28, 580-587.	2.8	133
3	Comparison of the Euroimmun Borrelia â€~antibody index' with Virotech immunoblot-based detection of intrathecal Borrelia antibody production for the diagnosis of Lyme neuroborreliosis. European Journal of Clinical Microbiology and Infectious Diseases, 2022, 41, 155-161.	1.3	0
4	Toxoplasmosis after allogeneic haematopoietic cell transplantation: experience using a PCR-guided pre-emptive approach. Clinical Microbiology and Infection, 2022, 28, 440-445.	2.8	5
5	Prospective assessment of breakthrough infections and neurotoxicity and their association with cefepime trough concentrations in patients with febrile neutropenia. International Journal of Antimicrobial Agents, 2022, 59, 106472.	1.1	7
6	Molecular identification and azole susceptibility testing of Aspergillus section Fumigati isolated from soil samples in Lebanon. Journal De Mycologie Medicale, 2022, 32, 101242.	0.7	2
7	Comment on: Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes. Journal of Antimicrobial Chemotherapy, 2022, 77, 1209-1210.	1.3	6
8	The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe, The, 2022, 3, e543-e552.	3.4	255
9	Innovative FO-SPR Label-free Strategy for Detecting Anti-RBD Antibodies in COVID-19 Patient Serum and Whole Blood. ACS Sensors, 2022, 7, 477-487.	4.0	31
10	Disseminated histoplasmosis diagnosed by cross-reactivity with the Aspergillus galactomannan antigen in an HIV-positive patient. Journal De Mycologie Medicale, 2022, 32, 101244.	0.7	5
11	Blood culture surveillance in a secondary care hospital in Benin: epidemiology of bloodstream infection pathogens and antimicrobial resistance. BMC Infectious Diseases, 2022, 22, 119.	1.3	9
12	Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection. Diagnostic Microbiology and Infectious Disease, 2022, 103, 115659.	0.8	44
13	Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study. Infectious Diseases and Therapy, 2022, 11, 827-840.	1.8	13
14	Prognostic Impact of Bronchoalveolar Lavage Fluid Galactomannan and Aspergillus Culture Results on Survival in COVID-19 Intensive Care Unit Patients: a <i>Post Hoc</i> Analysis from the European Confederation of Medical Mycology (ECMM) COVID-19-Associated Pulmonary Aspergillosis Study. Journal of Clinical Microbiology, 2022, 60, e0229821.	1.8	17
15	Longitudinal multimodal imaging-compatible mouse model of triazole-sensitive and -resistant invasive pulmonary aspergillosis. DMM Disease Models and Mechanisms, 2022, 15, .	1.2	12
16	Isavuconazole in the Treatment of Aspergillus fumigatus Fracture-Related Infection: Case Report and Literature Review. Antibiotics, 2022, 11, 344.	1.5	3
17	Overcome Double Trouble: Baloxavir Marboxil Suppresses Influenza Thereby Mitigating Secondary Invasive Pulmonary Aspergillosis. Journal of Fungi (Basel, Switzerland), 2022, 8, 1.	1.5	12
18	Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications. Journal of Antimicrobial Chemotherapy, 2022, 77, 2053-2073.	1.3	27

#	Article	IF	CITATIONS
19	Nationwide Harmonization Effort for Semi-Quantitative Reporting of SARS-CoV-2 PCR Test Results in Belgium. Viruses, 2022, 14, 1294.	1.5	13
20	Systematic Comparison of Hospital-Wide Standard and Model-Based Therapeutic Drug Monitoring of Vancomycin in Adults. Pharmaceutics, 2022, 14, 1459.	2.0	1
21	Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection by a Phylogenetically Distinct Strain. Clinical Infectious Diseases, 2021, 73, 354-356.	2.9	218
22	Prospective Evaluation of the Turbidimetric β-D-Glucan Assay and 2 Lateral Flow Assays on Serum in Invasive Aspergillosis. Clinical Infectious Diseases, 2021, 72, 1577-1584.	2.9	24
23	Dynamic changes in paediatric invasive pneumococcal disease after sequential switches of conjugate vaccine in Belgium: a national retrospective observational study. Lancet Infectious Diseases, The, 2021, 21, 127-136.	4.6	34
24	Trehalose as quantitative biomarker for in vivo diagnosis and treatment follow-up in cryptococcomas. Translational Research, 2021, 230, 111-122.	2.2	11
25	In-depth analysis of pneumococcal serotypes in Belgian children (2015–2018): Diversity, invasive disease potential, and antimicrobial susceptibility in carriage and disease. Vaccine, 2021, 39, 372-379.	1.7	14
26	Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirusâ€2 (SARSâ€CoVâ€2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies. British Journal of Haematology, 2021, 192, 1100-1105.	1.2	51
27	Immunoassays for anti-SARS-CoV-2 antibodies: recent insights. Lancet Infectious Diseases, The, 2021, 21, e120.	4.6	4
28	CryptoCEST: A promising tool for spatially resolved identification of fungal brain lesions and their differentiation from brain tumors with MRI. NeuroImage: Clinical, 2021, 31, 102737.	1.4	5
29	The effectiveness of Check of Medication Appropriateness for antimicrobial stewardship: an interrupted time series analysis. Journal of Antimicrobial Chemotherapy, 2021, 77, 259-267.	1.3	4
30	TREM1 regulates antifungal immune responses in invasive pulmonary aspergillosis. Virulence, 2021, 12, 570-583.	1.8	3
31	Underlying factors in paediatric invasive pneumococcal disease in Belgium – Authors' reply. Lancet Infectious Diseases, The, 2021, 21, 170.	4.6	0
32	Antifungal Prophylaxis After Lung Transplantation: Where Are We Now?. Transplantation, 2021, 105, 2538-2545.	0.5	5
33	First Investigative Study of Azole-Resistant Aspergillus fumigatus in the Environment in Burkina Faso. International Journal of Environmental Research and Public Health, 2021, 18, 2250.	1.2	11
34	<i>Pneumocystis jirovecii</i> Disease: Basis for the Revised EORTC/MSGERC Invasive Fungal Disease Definitions in Individuals Without Human Immunodeficiency Virus. Clinical Infectious Diseases, 2021, 72, S114-S120.	2.9	50
35	Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infection. Journal of Clinical Virology, 2021, 136, 104765.	1.6	112
36	Genomics of an endemic cystic fibrosis Burkholderia multivorans strain reveals low within-patient evolution but high between-patient diversity. PLoS Pathogens, 2021, 17, e1009418.	2.1	11

#	Article	IF	CITATIONS
37	Triazole-Resistance in Environmental Aspergillus fumigatus in Latin American and African Countries. Journal of Fungi (Basel, Switzerland), 2021, 7, 292.	1.5	16
38	Neuraminidase and SIGLEC15 modulate the host defense against pulmonary aspergillosis. Cell Reports Medicine, 2021, 2, 100289.	3.3	15
39	Tick borne relapsing fever after travelling to a Greek island. Journal of Travel Medicine, 2021, , .	1.4	Ο
40	Concomitant use of isavuconazole and CYP3A4/5 inducers: Where pharmacogenetics meets pharmacokinetics. Mycoses, 2021, 64, 1111-1116.	1.8	3
41	Genetic Variation in PFKFB3 Impairs Antifungal Immunometabolic Responses and Predisposes to Invasive Pulmonary Aspergillosis. MBio, 2021, 12, e0036921.	1.8	6
42	Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial. Intensive Care Medicine, 2021, 47, 674-686.	3.9	49
43	Fluconazole Underexposure in Critically III Patients: a Matter of Using the Right Targets?. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	1
44	A confirmed case of COVID-19 reinfection with a genetically distinct strain: a case report from Belgium. Acta Clinica Belgica, 2021, , 1-2.	0.5	0
45	Comparison of Two Commercial Colorimetric Broth Microdilution Tests for Candida Susceptibility Testing: Sensititre YeastOne versus MICRONAUT-AM. Journal of Fungi (Basel, Switzerland), 2021, 7, 356.	1.5	9
46	Cov-MS: A Community-Based Template Assay for Mass-Spectrometry-Based Protein Detection in SARS-CoV-2 Patients. Jacs Au, 2021, 1, 750-765.	3.6	29
47	Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. Intensive Care Medicine, 2021, 47, 819-834.	3.9	106
48	Comparison of the Quantitative DiaSorin Liaison Antigen Test to Reverse Transcription-PCR for the Diagnosis of COVID-19 in Symptomatic and Asymptomatic Outpatients. Journal of Clinical Microbiology, 2021, 59, e0037421.	1.8	31
49	Serum amyloid P component is an essential element of resistance against Aspergillus fumigatus. Nature Communications, 2021, 12, 3739.	5.8	18
50	Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity. Nature Communications, 2021, 12, 4117.	5.8	170
51	Diagnosis and treatment of COVID-19 associated pulmonary apergillosis in critically ill patients: results from a European confederation of medical mycology registry. Intensive Care Medicine, 2021, 47, 1158-1160.	3.9	43
52	No <i>in vitro</i> activity of cefiderocol against OXA-427-producing Enterobacterales. Journal of Antimicrobial Chemotherapy, 2021, 76, 3317-3318.	1.3	7
53	Aspergillus Test Profiles and Mortality in Critically Ill COVID-19 Patients. Journal of Clinical Microbiology, 2021, 59, e0122921.	1.8	50
54	Liver and/or Kidney Transplantation After SARS-CoV-2 Infection. Transplantation, 2021, Publish Ahead of Print, .	0.5	2

#	Article	IF	CITATIONS
55	Concomitant Treatment with Voriconazole and Flucloxacillin: A Combination to Avoid. Antibiotics, 2021, 10, 1112.	1.5	5
56	Interaction between flucloxacillin and azoles: is isavuconazole next?. Mycoses, 2021, 64, 1508-1511.	1.8	3
57	COVID-19 associated pulmonary aspergillosis: regional variation in incidence and diagnostic challenges. Intensive Care Medicine, 2021, 47, 1339-1340.	3.9	27
58	Stable prevalence of triazole-resistance in Aspergillus fumigatus complex clinical isolates in a Belgian tertiary care center from 2016 to 2020. Journal of Infection and Chemotherapy, 2021, 27, 1774-1778.	0.8	6
59	Early oseltamivir reduces risk for influenza-associated aspergillosis in a double-hit murine model. Virulence, 2021, 12, 2493-2508.	1.8	20
60	Pharmacokinetic Variability and Target Attainment of Fluconazole in Critically Ill Patients. Microorganisms, 2021, 9, 2068.	1.6	8
61	Critical influenza and prophylactic antifungal therapy for aspergillosis: a nuanced approach to a pertinent infectious disease. Intensive Care Medicine, 2021, 47, 1343-1344.	3.9	Ο
62	Multinational Observational Cohort Study of COVID-19–Associated Pulmonary Aspergillosis1. Emerging Infectious Diseases, 2021, 27, 2892-2898.	2.0	82
63	Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb. Cell, 2021, 184, 5932-5949.e15.	13.5	245
64	Evaluation of the SARS-CoV-2 positivity ratio and upper respiratory tract viral load among asymptomatic individuals screened before hospitalization or surgery in Flanders, Belgium. PLoS ONE, 2021, 16, e0259908.	1.1	1
65	A Visual and Comprehensive Review on COVID-19-Associated Pulmonary Aspergillosis (CAPA). Journal of Fungi (Basel, Switzerland), 2021, 7, 1067.	1.5	52
66	First case of Candida auris infection in Belgium in a surgical patient from Kuwait. Acta Clinica Belgica, 2020, 75, 221-228.	0.5	14
67	Clinical and biochemical differences between hantavirus infection and leptospirosis: a retrospective analysis of a patient series in Belgium. Acta Clinica Belgica, 2020, 75, 185-192.	0.5	3
68	Lateral flow assays for diagnosing invasive pulmonary aspergillosis in adult hematology patients: A comparative multicenter study. Medical Mycology, 2020, 58, 444-452.	0.3	50
69	Pathogenesis and management of fracture-related infection. Clinical Microbiology and Infection, 2020, 26, 572-578.	2.8	135
70	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clinical Infectious Diseases, 2020, 71, 1367-1376.	2.9	1,429
71	The Fungal PCR Initiative's evaluation of in-house and commercial Pneumocystis jirovecii qPCR assays: Toward a standard for a diagnostics assay. Medical Mycology, 2020, 58, 779-788.	0.3	39
72	Diagnosis of Breakthrough Fungal Infections in the Clinical Mycology Laboratory: An ECMM Consensus Statement. Journal of Fungi (Basel, Switzerland), 2020, 6, 216.	1.5	21

#	Article	IF	CITATIONS
73	Belgian National Survey on Tinea Capitis: Epidemiological Considerations and Highlight of Terbinafine-Resistant T. mentagrophytes with a Mutation on SQLE Gene. Journal of Fungi (Basel,) Tj ETQq1 1 0.78	4 3.5 4 rgBT	B verlock 1
74	Proteome analysis of bronchoalveolar lavage fluids reveals host and fungal proteins highly expressed during invasive pulmonary aspergillosis in mice and humans. Virulence, 2020, 11, 1337-1351.	1.8	8
75	Cefepime therapeutic drug monitoring: Evaluation of agreement between peripheral and central venous blood sampling. Clinica Chimica Acta, 2020, 510, 450-454.	0.5	1
76	The Added Value of Longitudinal Imaging for Preclinical <i>In Vivo</i> Efficacy Testing of Therapeutic Compounds against Cerebral Cryptococcosis. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	10
77	Community-acquired bacterial meningitis in adults: emergency department management protocol. Acta Neurologica Belgica, 2020, 120, 1033-1043.	0.5	0
78	Amphotericin B and Other Polyenes—Discovery, Clinical Use, Mode of Action and Drug Resistance. Journal of Fungi (Basel, Switzerland), 2020, 6, 321.	1.5	126
79	Variable Correlation between Bronchoalveolar Lavage Fluid Fungal Load and Serum-(1,3)-β-d-Glucan in Patients with Pneumocystosis—A Multicenter ECMM Excellence Center Study. Journal of Fungi (Basel,) Tj ETQq1	1.0 .7843	1 4 2rgBT /O∨
80	The one health problem of azole resistance in Aspergillus fumigatus: current insights and future research agenda. Fungal Biology Reviews, 2020, 34, 202-214.	1.9	68
81	Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs. Clinical Microbiology and Infection, 2020, 26, 1557.e1-1557.e7.	2.8	124
82	Disseminated histoplasmosis in a kidney liver transplant patient from a non-endemic area: A diagnostic challenge. IDCases, 2020, 22, e00971.	0.4	3
83	Successful Outcome of Disseminated Fusarium musae Fungemia with Skin Localization Treated with Liposomal Amphotericin B and Voriconazole in a Patient with Acute Myeloid Leukemia. Mycopathologia, 2020, 185, 1085-1089.	1.3	3
84	Hmg1 Gene Mutation Prevalence in Triazole-Resistant Aspergillus fumigatus Clinical Isolates. Journal of Fungi (Basel, Switzerland), 2020, 6, 227.	1.5	12
85	Diagnosis of Invasive Aspergillosis in Intensive Care Unit Patients. Current Fungal Infection Reports, 2020, 14, 166-173.	0.9	2
86	Fetal Diagnosis and Therapy during the COVID-19 Pandemic: Guidance on Behalf of the International Fetal Medicine and Surgery Society. Fetal Diagnosis and Therapy, 2020, 47, 689-698.	0.6	25
87	Phagosomal removal of fungal melanin reprograms macrophage metabolism to promote antifungal immunity. Nature Communications, 2020, 11, 2282.	5.8	68
88	Successful <i>Pseudomonas aeruginosa</i> eradication improves outcomes after lung transplantation: a retrospective cohort analysis. European Respiratory Journal, 2020, 56, 2001720.	3.1	22
89	Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context. Frontiers in Medicine, 2020, 7, 225.	1.2	171
90	Diagnostic performance of seven rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients. Clinical Microbiology and Infection, 2020, 26, 1082-1087.	2.8	221

#	Article	IF	CITATIONS
91	Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Medicine, 2020, 46, 1524-1535.	3.9	278
92	European confederation of medical mycology expert consult—An ECMM excellence center initiative. Mycoses, 2020, 63, 566-572.	1.8	8
93	â€~Pathogenesis and management of fracture-related infection' – Author's reply. Clinical Microbiology and Infection, 2020, 26, 652-653.	2.8	3
94	Tintelnotia destructans as an emerging opportunistic pathogen: First case of T. destructans superinfection in herpetic keratitis. American Journal of Ophthalmology Case Reports, 2020, 19, 100791.	0.4	5
95	Pathogenic Allodiploid Hybrids of Aspergillus Fungi. Current Biology, 2020, 30, 2495-2507.e7.	1.8	39
96	Analytical Performance of the RIDASCREEN® Hantavirus Puumala IgG/IgM ELISA Assay. Viruses, 2020, 12, 226.	1.5	1
97	A Mortality Prediction Rule for Hematology Patients with Invasive Aspergillosis Based on Serum Galactomannan Kinetics. Journal of Clinical Medicine, 2020, 9, 610.	1.0	10
98	Efficacy and safety of a Belgian tertiary care outpatient parenteral antimicrobial therapy (OPAT) program. Infection, 2020, 48, 357-366.	2.3	31
99	The impact of childhood 13-valent pneumococcal conjugate vaccination on overall invasive pneumococcal disease, including the oldest old. Acta Clinica Belgica, 2020, 76, 1-8.	0.5	5
100	Laboratory information system requirements to manage the COVID-19 pandemic: A report from the Belgian national reference testing center. Journal of the American Medical Informatics Association: JAMIA, 2020, 27, 1293-1299.	2.2	22
101	Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes. Journal of Antimicrobial Chemotherapy, 2020, 75, 1807-1819.	1.3	37
102	Solid organ donation after death from listeria encephalitis: A case report. Transplant Infectious Disease, 2020, 22, e13295.	0.7	2
103	Polymorphisms within the <i>ARNT2</i> and <i>CX3CR1</i> Genes Are Associated with the Risk of Developing Invasive Aspergillosis. Infection and Immunity, 2020, 88, .	1.0	8
104	Functional Characterization of Clinical Isolates of the Opportunistic Fungal Pathogen Aspergillus nidulans. MSphere, 2020, 5, .	1.3	32
105	Comparison of the diagnostic performance with whole blood and plasma of four rapid antibody tests for SARS-CoV-2. Clinical Chemistry and Laboratory Medicine, 2020, 58, e197-e199.	1.4	12
106	Bacterial contamination of blood products for transfusion in the Democratic Republic of the Congo: temperature monitoring, qualitative and semi-quantitative culture. Blood Transfusion, 2020, 18, 348-358.	0.3	0
107	Gliotoxin and bis(methylthio)gliotoxin are not reliable as biomarkers of invasive aspergillosis. Mycoses, 2019, 62, 945-948.	1.8	6
108	ECMM <i>Candi</i> Reg—A ready to use platform for outbreaks and epidemiological studies. Mycoses, 2019, 62, 920-927.	1.8	19

#	ARTICLE	IF	CITATIONS
109	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infectious Diseases, The, 2019, 19, e405-e421.	4.6	970
110	A decade of enterovirus genetic diversity in Belgium. Journal of Clinical Virology, 2019, 121, 104205.	1.6	9
111	Hospital Laboratory Survey for Identification of Candida auris in Belgium. Journal of Fungi (Basel,) Tj ETQq1 1 0.7	84314 rgB 1.5	BT /Overlock
112	Infectious disease consultation lowers candidaemia mortality. Lancet Infectious Diseases, The, 2019, 19, 1270-1272.	4.6	7
113	Longitudinal InÂVivo Assessment of Host-Microbe Interactions in a Murine Model of Pulmonary Aspergillosis. IScience, 2019, 20, 184-194.	1.9	7
114	Comment on: Improving access to appropriate post-exposure doxycycline for Lyme disease prophylaxis: role for community pharmacies. Journal of Antimicrobial Chemotherapy, 2019, 74, 1464-1465.	1.3	0
115	Prevalence of voriconazole-resistant invasive aspergillosis and its impact on mortality in haematology patients. Journal of Antimicrobial Chemotherapy, 2019, 74, 2759-2766.	1.3	52
116	Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. Critical Care, 2019, 23, 219.	2.5	123
117	Sensitive bioluminescence imaging of fungal dissemination to the brain in mouse models of cryptococcosis. DMM Disease Models and Mechanisms, 2019, 12, .	1.2	28
118	Systemic antifungal drug use in Belgium—One of the biggest antifungal consumers in Europe. Mycoses, 2019, 62, 542-550.	1.8	8
119	Beta- <scp>d</scp> -Glucan for Diagnosing <i>Pneumocystis</i> Pneumonia: a Direct Comparison between the Wako β-Glucan Assay and the Fungitell Assay. Journal of Clinical Microbiology, 2019, 57, .	1.8	31
120	Standards of CARE: what is considered â€~best practice' for the management of invasive fungal infections? A haematologist's and a mycologist's perspective. Journal of Antimicrobial Chemotherapy, 2019, 74, ii3-ii8.	1.3	3
121	Migrating a lab-developed MERS-CoV real-time PCR to 3 "Sample to Result―systems: experiences on optimization and validation. Diagnostic Microbiology and Infectious Disease, 2019, 94, 349-354.	0.8	4
122	Development and validation of the European QUALity (EQUAL) score for mucormycosis management in haematology. Journal of Antimicrobial Chemotherapy, 2019, 74, 1704-1712.	1.3	25
123	Potential of Gallium as an Antifungal Agent. Frontiers in Cellular and Infection Microbiology, 2019, 9, 414.	1.8	28
124	Clostridium difficile infection in inflammatory bowel disease: epidemiology over two decades. European Journal of Gastroenterology and Hepatology, 2019, 31, 668-673.	0.8	9
125	Serial Detection of Circulating Mucorales DNA in Invasive Mucormycosis: A Retrospective Multicenter Evaluation. Journal of Fungi (Basel, Switzerland), 2019, 5, 113.	1.5	32
126	Active neuroborreliosis or inflammation: are the diagnostic guidelines at stake?. Acta Neurologica Belgica, 2019, 119, 207-214.	0.5	1

#	Article	IF	CITATIONS
127	Monitoring of Fluconazole and Caspofungin Activity against <i>In Vivo</i> Candida glabrata Biofilms by Bioluminescence Imaging. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	22
128	Letermovir for prophylaxis of cytomegalovirus manifestations in adult allogeneic hematopoietic stem cell transplant recipients. Future Microbiology, 2019, 14, 175-184.	1.0	3
129	Diagnosing Invasive Pulmonary Aspergillosis in Hematology Patients: a Retrospective Multicenter Evaluation of a Novel Lateral Flow Device. Journal of Clinical Microbiology, 2019, 57, .	1.8	21
130	Prevalence, geographic risk factor, and development of a standardized protocol for fungal isolation in cystic fibrosis: Results from the international prospective study "MFIP― Journal of Cystic Fibrosis, 2019, 18, 212-220.	0.3	38
131	Bronchoscopic fibered confocal fluorescence microscopy for longitudinal in vivo assessment of pulmonary fungal infections in free-breathing mice. Scientific Reports, 2018, 8, 3009.	1.6	18
132	EQUAL Candida Score: An <scp>ECMM</scp> score derived from current guidelines to measure QUAlity of Clinical Candidaemia Management. Mycoses, 2018, 61, 326-330.	1.8	60
133	Antibiotic Resistance Plasmids Cointegrated into a Megaplasmid Harboring the <i>bla</i> _{OXA-427} Carbapenemase Gene. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	20
134	Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clinical Microbiology and Infection, 2018, 24, e1-e38.	2.8	942
135	Triazole resistance surveillance in Aspergillus fumigatus. Medical Mycology, 2018, 56, S83-S92.	0.3	114
136	Antifungal Activity of Oleylphosphocholine on <i>In Vitro</i> and <i>In Vivo Candida albicans</i> Biofilms. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	12
137	Increasing candidaemia incidence from 2004 to 2015 with a shift in epidemiology in patients preexposed to antifungals. Mycoses, 2018, 61, 127-133.	1.8	47
138	967. Inhibition of Host Neuraminidase Increases Susceptibility to Invasive Pulmonary Aspergillosis. Open Forum Infectious Diseases, 2018, 5, S36-S36.	0.4	11
139	Distribution of HCV genotypes in Belgium from 2008 to 2015. PLoS ONE, 2018, 13, e0207584.	1.1	6
140	Switch in childhood pneumococcal vaccine in Belgium. Lancet Infectious Diseases, The, 2018, 18, 945-946.	4.6	3
141	A Multimodal Imaging Approach Enables <i>In Vivo</i> Assessment of Antifungal Treatment in a Mouse Model of Invasive Pulmonary Aspergillosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	23
142	Clonal Spread of Candida glabrata Bloodstream Isolates and Fluconazole Resistance Affected by Prolonged Exposure: a 12-Year Single-Center Study in Belgium. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	16
143	Switch in a childhood pneumococcal vaccination programme from PCV13 to PCV10: a defendable approach?. Lancet Infectious Diseases, The, 2018, 18, 830-831.	4.6	39
144	Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respiratory Medicine,the, 2018, 6, 782-792.	5.2	638

#	Article	IF	CITATIONS
145	Anidulafungin increases the antibacterial activity of tigecycline in polymicrobial Candida albicans/Staphylococcus aureus biofilms on intraperitoneally implanted foreign bodies. Journal of Antimicrobial Chemotherapy, 2018, 73, 2806-2814.	1.3	23
146	A Framework for Understanding the Evasion of Host Immunity by Candida Biofilms. Frontiers in Immunology, 2018, 9, 538.	2.2	11
147	Azole-Resistance in Aspergillus terreus and Related Species: An Emerging Problem or a Rare Phenomenon?. Frontiers in Microbiology, 2018, 9, 516.	1.5	66
148	Galactomannan, a Surrogate Marker for Outcome in Invasive Aspergillosis: Finally Coming of Age. Frontiers in Microbiology, 2018, 9, 661.	1.5	60
149	Genetic deficiency of NOD2 confers resistance to invasive aspergillosis. Nature Communications, 2018, 9, 2636.	5.8	38
150	Aspergillus fumigatus Detection and Risk Factors in Patients with COPD–Bronchiectasis Overlap. International Journal of Molecular Sciences, 2018, 19, 523.	1.8	27
151	Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. Microbial Cell, 2018, 5, 300-326.	1.4	81
152	Global guidelines and initiatives from the European Confederation of Medical Mycology to improve patient care and research worldwide: New leadership is about working together. Mycoses, 2018, 61, 885-894.	1.8	52
153	Determining the analytical specificity of PCR-based assays for the diagnosis of IA: What is <i>Aspergillus</i> ?. Medical Mycology, 2017, 55, myw093.	0.3	24
154	Candida and its dual lifestyle as a commensal and a pathogen. Research in Microbiology, 2017, 168, 802-810.	1.0	58
155	A prospective international Aspergillus terreus survey: an EFISG, ISHAM and ECMM joint study. Clinical Microbiology and Infection, 2017, 23, 776.e1-776.e5.	2.8	42
156	Improving outcome of fungal diseases – Guiding experts and patients towards excellence. Mycoses, 2017, 60, 420-425.	1.8	61
157	Culture-Based Methods and Molecular Tools for Azole-Resistant Aspergillus fumigatus Detection in a Belgian University Hospital. Journal of Clinical Microbiology, 2017, 55, 2391-2399.	1.8	35
158	<i>Pneumocystis jirovecii</i> pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients—authors' response. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw580.	1.3	13
159	Invasive Candida Infections in Liver Transplant Recipients: Clinical Features and Risk Factors for Mortality. Transplantation Direct, 2017, 3, e156.	0.8	34
160	lL-10 overexpression predisposes to invasive aspergillosis by suppressing antifungal immunity. Journal of Allergy and Clinical Immunology, 2017, 140, 867-870.e9.	1.5	37
161	Analytical and clinical comparison of Elecsys syphilis (Roche®) – Architect syphilis TP and reformulated Architect syphilis TP (Abbott®) assay. Diagnostic Microbiology and Infectious Disease, 2017, 87, 210-212.	0.8	1
162	Multicentre validation of 4-well azole agar plates as a screening method for detection of clinically relevant azole-resistant Aspergillus fumigatus. Journal of Antimicrobial Chemotherapy, 2017, 72, 3325-3333.	1.3	39

#	Article	IF	CITATIONS
163	Importance of Resolving Fungal Nomenclature: the Case of Multiple Pathogenic Species in the <i>Cryptococcus</i> Genus. MSphere, 2017, 2, .	1.3	124
164	Diversity of Pneumocystis jirovecii Across Europe: A Multicentre Observational Study. EBioMedicine, 2017, 22, 155-163.	2.7	20
165	Added diagnostic value and impact on antimicrobial therapy of 16S rRNA PCR and amplicon sequencing on resected heart valves in infective endocarditis: a prospective cohort study. Clinical Microbiology and Infection, 2017, 23, 888.e1-888.e5.	2.8	18
166	The microbiome-metabolome crosstalk in the pathogenesis of respiratory fungal diseases. Virulence, 2017, 8, 673-684.	1.8	25
167	Firstâ€inâ€man observation of <i>Talaromyces marneffei</i> â€transmission by organ transplantation. Mycoses, 2017, 60, 213-217.	1.8	17
168	Epidemiology and reporting of candidaemia in Belgium: a multi-centre study. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 649-655.	1.3	59
169	Sensitization to Aspergillus fumigatus as a risk factor for bronchiectasis in COPD. International Journal of COPD, 2017, Volume 12, 2629-2638.	0.9	38
170	Evaluation of Bronchoalveolar Lavage Fluid Cytokines as Biomarkers for Invasive Pulmonary Aspergillosis in At-Risk Patients. Frontiers in Microbiology, 2017, 8, 2362.	1.5	54
171	Comment on "A Cluster of Three Cases of <i> Hantavirus</i> Pulmonary Syndrome among Canadian Military Personnelâ€: Canadian Journal of Infectious Diseases and Medical Microbiology, 2016, 2016, 1-3.	0.7	3
172	Longitudinal, in vivo assessment of invasive pulmonary aspergillosis in mice by computed tomography and magnetic resonance imaging. Laboratory Investigation, 2016, 96, 692-704.	1.7	28
173	Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients. European Journal of Clinical Pharmacology, 2016, 72, 953-963.	0.8	21
174	â€~Bedside assessment' of acute hantavirus infections and their possible classification into the spectrum of haemophagocytic syndromes. European Journal of Clinical Microbiology and Infectious Diseases, 2016, 35, 1101-1106.	1.3	9
175	Cladophialophora bantiana osteomyelitis in a renal transplant patient. Medical Mycology Case Reports, 2016, 12, 17-20.	0.7	11
176	Broad-Range PCR Coupled with Electrospray Ionization Time of Flight Mass Spectrometry for Detection of Bacteremia and Fungemia in Patients with Neutropenic Fever. Journal of Clinical Microbiology, 2016, 54, 2513-2520.	1.8	20
177	ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. Journal of Antimicrobial Chemotherapy, 2016, 71, 2386-2396.	1.3	226
178	<i>Mycobacterium genavense</i> infection in a solid organ recipient: a diagnostic and therapeutic challenge. Transplant Infectious Disease, 2016, 18, 125-131.	0.7	17
179	PCR-based detection of <i>Aspergillus fumigatus Cyp51A</i> mutations on bronchoalveolar lavage: a multicentre validation of the AsperGenius assay [®] in 201 patients with haematological disease suspected for invasive aspergillosis. Journal of Antimicrobial Chemotherapy, 2016, 71, 3528-3535.	1.3	114
180	Comparison of PCR-Electrospray Ionization Mass Spectrometry with 16S rRNA PCR and Amplicon Sequencing for Detection of Bacteria in Excised Heart Valves. Journal of Clinical Microbiology, 2016, 54, 2825-2831.	1.8	16

#	Article	IF	CITATIONS
181	Development of a national EUCAST challenge panel for antimicrobial susceptibility testing. Clinical Microbiology and Infection, 2016, 22, 704-710.	2.8	9
182	Are hantavirus infections also part of the rapidly growing spectrum of an infection-triggered reactive haemophagocytic syndrome?. Clinical Microbiology and Infection, 2016, 22, 745-746.	2.8	2
183	Typing of Pneumocystis jirovecii by multilocus sequencing: evidence of outbreak?. European Journal of Clinical Microbiology and Infectious Diseases, 2016, 35, 911-916.	1.3	11
184	ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. Journal of Antimicrobial Chemotherapy, 2016, 71, 2397-2404.	1.3	211
185	Pretreatment of Bronchoalveolar Lavage Fluid Samples with SLsolution Leads to False-Negative Aspergillus Galactomannan Levels. Journal of Clinical Microbiology, 2016, 54, 1171-1171.	1.8	3
186	Plasmalyte: No Longer a Culprit in Causing False-Positive Galactomannan Test Results. Journal of Clinical Microbiology, 2016, 54, 795-797.	1.8	15
187	EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents. Clinical Microbiology and Infection, 2016, 22, 571.e1-571.e4.	2.8	104
188	Diagnostic Performance of Galactomannan Antigen Testing in Cerebrospinal Fluid. Journal of Clinical Microbiology, 2016, 54, 428-431.	1.8	67
189	Burden of serious fungal infections in Belgium. Mycoses, 2015, 58, 1-5.	1.8	21
190	Acute ataxic neuropathy associated with hepatitis E virus infection. Muscle and Nerve, 2015, 52, 464-465.	1.0	9
191	Nationwide Surveillance of Azole Resistance in Aspergillus Diseases. Antimicrobial Agents and Chemotherapy, 2015, 59, 4569-4576.	1.4	81
192	Clinical Performance of Aspergillus PCR for Testing Serum and Plasma: a Study by the European Aspergillus PCR Initiative. Journal of Clinical Microbiology, 2015, 53, 2832-2837.	1.8	105
193	Invasive Aspergillosis After Kidney Transplant: Case-Control Study. Clinical Infectious Diseases, 2015, 60, 1505-1511.	2.9	38
194	Evaluation of different confirmatory algorithms using seven treponemal tests on Architect Syphilis TP-positive/RPR-negative sera. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 2041-2048.	1.3	8
195	New echinocandin susceptibility patterns for nosocomial Candida albicans in BogotÃ _i , Colombia, in ten tertiary care centres: an observational study. BMC Infectious Diseases, 2015, 15, 108.	1.3	5
196	Investigation of Saliva as an Alternative to Plasma Monitoring of Voriconazole. Clinical Pharmacokinetics, 2015, 54, 1151-1160.	1.6	15
197	Analytical Comparison of <i>In Vitro</i> -Spiked Human Serum and Plasma for PCR-Based Detection of Aspergillus fumigatus DNA: a Study by the European Aspergillus PCR Initiative. Journal of Clinical Microbiology, 2015, 53, 2838-2845.	1.8	40
198	Prospective Multicenter International Surveillance of Azole Resistance in <i>Aspergillus fumigatus</i> . Emerging Infectious Diseases, 2015, 21, 1041-1044.	2.0	302

#	Article	IF	CITATIONS
199	International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resistance Updates, 2015, 21-22, 30-40.	6.5	262
200	In vivo Candida glabrata biofilm development on foreign bodies in a rat subcutaneous model. Journal of Antimicrobial Chemotherapy, 2015, 70, 846-856.	1.3	46
201	Comparison of two automated immunoassays for the determination of Puumalavirus IgM and IgG. Journal of Clinical Virology, 2014, 60, 165-167.	1.6	4
202	ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clinical Microbiology and Infection, 2014, 20, 27-46.	2.8	383
203	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. Clinical Microbiology and Infection, 2014, 20, 47-75.	2.8	262
204	ESCMID†and ECMMâ€j joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clinical Microbiology and Infection, 2014, 20, 5-26.	2.8	547
205	New case of azole-resistant Aspergillus fumigatus due to TR46/Y121F/T289A mutation in Belgium. Journal of Antimicrobial Chemotherapy, 2014, 69, 3439-3440.	1.3	16
206	Clinical outcome of parapneumonic empyema in children treated according to a standardized medical treatment. European Journal of Pediatrics, 2014, 173, 1339-1345.	1.3	14
207	Impact of Hypoalbuminemia on Voriconazole Pharmacokinetics in Critically III Adult Patients. Antimicrobial Agents and Chemotherapy, 2014, 58, 6782-6789.	1.4	52
208	Azole resistance in Aspergillus fumigatus. Current Opinion in Infectious Diseases, 2013, 26, 493-500.	1.3	175
209	Detection of Galactomannan in Bronchoalveolar Lavage Fluid Samples of Patients at Risk for Invasive Pulmonary Aspergillosis: Analytical and Clinical Validity. Journal of Clinical Microbiology, 2012, 50, 1258-1263.	1.8	159
210	Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study. Intensive Care Medicine, 2012, 38, 1761-1768.	3.9	220
211	High incidence of bloodstream infection detected by surveillance blood cultures in hematology patients on corticosteroid therapy. Supportive Care in Cancer, 2012, 20, 3013-3017.	1.0	13
212	Update on the Evolving Role of MALDI-TOF MS for Laboratory Diagnosis of Fungal Infections. Current Fungal Infection Reports, 2012, 6, 206-214.	0.9	8
213	Azole-resistant Aspergillus fumigatus due to TR46/Y121F/T289A mutation emerging in Belgium, July 2012. Eurosurveillance, 2012, 17, .	3.9	64
214	P1-387 Time series analysis performed on nephropathia epidemica in Belgium. Journal of Epidemiology and Community Health, 2011, 65, A174-A174.	2.0	0
215	Detailed comparison of Candida albicans and Candida glabrata biofilms under different conditions and their susceptibility to caspofungin and anidulafungin. Journal of Medical Microbiology, 2011, 60, 1261-1269.	0.7	103
216	Beta- <scp>d</scp> -Glucan Detection as a Diagnostic Test for Invasive Aspergillosis in Immunocompromised Critically III Patients with Symptoms of Respiratory Infection: an Autopsy-Based Study. Journal of Clinical Microbiology, 2011, 49, 3783-3787.	1.8	50

#	Article	IF	CITATIONS
217	Matrix-assisted laser desorption ionization-time of flight mass spectrometry for the identification of bacteria and yeasts in a clinical microbiological laboratory: a review. Acta Clinica Belgica, 2011, 66, 267-73.	0.5	41
218	Candida albicans biofilm formation in a new in vivo rat model. Microbiology (United Kingdom), 2010, 156, 909-919.	0.7	97
219	Reply to Rijnders and Slobbe and to Donnelly and Leeflang. Clinical Infectious Diseases, 2010, 50, 1071-1073.	2.9	5
220	Increasing Incidence of Mucormycosis in University Hospital, Belgium. Emerging Infectious Diseases, 2010, 16, 1456-1458.	2.0	89
221	Evaluation of the New Architect Cytomegalovirus Immunoglobulin M (IgM), IgG, and IgG Avidity Assays. Journal of Clinical Microbiology, 2009, 47, 1695-1699.	1.8	76
222	Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study. Intensive Care Medicine, 2009, 35, 1526-1531.	3.9	188
223	OC08.03: Cytomegalovirus: a retrospective comparative analysis of fetal ultrasound and magnetic resonance imaging in predicting fetal outcome. Ultrasound in Obstetrics and Gynecology, 2009, 34, 13-14.	0.9	0
224	Galactomannan in Bronchoalveolar Lavage Fluid. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 27-34.	2.5	457
225	Invasive Aspergillosis in the Intensive Care Unit. Clinical Infectious Diseases, 2007, 45, 205-216.	2.9	306
226	Fungemia at a tertiary care hospital: incidence, therapy, and distribution and antifungal susceptibility of causative species. European Journal of Clinical Microbiology and Infectious Diseases, 2007, 26, 541-547.	1.3	46
227	Zoonotic transmission of <i>Cryptococcus neoformans</i> from a magpie to an immunocompetent patient. Journal of Internal Medicine, 2005, 257, 385-388.	2.7	63
228	Fatal pulmonary infection in a leukaemic patient caused by Hormographiella aspergillata. Journal of Medical Microbiology, 2005, 54, 685-688.	0.7	36
229	Macrolide resistance in Belgian Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy, 2000, 45, 119-121.	1.3	46
230	Prospective Study of Catalase-positive Coryneform Organisms in Clinical Specimens: Identification, Clinical Relevance, and Antibiotic Susceptibility. Diagnostic Microbiology and Infectious Disease, 1998, 30, 7-15.	0.8	61